for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

AEterna Zentaris Inc. (USA)

AEZS.OQ

Latest Trade

1.05USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

0.83

 - 

5.56

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
1.05
Open
--
Volume
--
3M AVG Volume
3.12
Today's High
--
Today's Low
--
52 Week High
5.56
52 Week Low
0.83
Shares Out (MIL)
19.96
Market Cap (MIL)
21.59
Forward P/E
0.59
Dividend (Yield %)
--

Latest Developments

More

Aeterna Zentaris Announces Appointment Of New President And CEO

Aeterna Zentaris Reports Qtrly Loss Per Share Of $0.01

Aeterna Zentaris Inc Files For Mixed Shelf Of Up To $45 Million

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About AEterna Zentaris Inc. (USA)

Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women's health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others. The Company's principal product candidates are Zoptrex (zoptarelin doxorubicin) and Macrilen (macimorelin) in oncology and endocrinology. The Company focuses on its product candidates Zoptrex and Macrilen, which are in Phase III clinical development, and on a luteinizing hormone-releasing hormone (LHRH)-disorazol Z conjugate (AEZS-138), which is in pre-clinical development in oncology and is available for partnering. The Company's direct and indirect subsidiaries include AEZS GmbH, Zentaris IVF GmbH and Aeterna Zentaris, Inc.

Industry

Biotechnology & Drugs

Contact Info

315 Sigma Dr Ste 302D

+1.843.9003223

http://www.aezsinc.com/

Executive Leadership

Carolyn Egbert

Independent Chairman of the Board

Klaus Paulini

President, Chief Executive Officer

Leslie Auld

Chief Financial Officer, Senior Vice President

Richard Sachse

Senior Vice President, Chief Scientific Officer, Chief Medical Officer

Jude P Dinges

Chief Commercial Officer, Senior Vice President

Key Stats

2.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-2.410

2017

-1.360

2018

0.250

2019(E)

1.770
Price To Earnings (TTM)
--
Price To Sales (TTM)
9.45
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
-62.09
Return on Equity (TTM)
-47.11

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up